Table 1.
Baseline characteristics classified by underlying kidney diseases
| Total (N=764) | Glomerular (N=292, 38.2%) | Vascular (N=131, 17.1%) | Interstitial/PN/Uropathy (N=45, 5.9%) | Diabetic (N=82, 10.7%) | Hereditary and various (N=73, 9.6%) | Unknown (N=141, 18.5%) | |
|---|---|---|---|---|---|---|---|
| Era | |||||||
| 1995–2000 | 173 (22.6) | 72 (24.7) | 33 (25.2) | 12 (26.7) | 4 (4.9) | 13 (17.8) | 39 (27.7) |
| 2001–2005 | 235 (30.8) | 89 (30.5) | 45 (34.4) | 15 (33.3) | 23 (28.0) | 19 (26.0) | 44 (31.2) |
| 2006–2010 | 356 (46.6) | 131 (44.8) | 53 (40.4) | 18 (40.0) | 55 (67.1) | 41 (56.2) | 58 (41.1) |
| HLA mismatch | |||||||
| Unknown | 22 (2.9) | 8 (2.7) | 0 (0) | 0 (0) | 4 (4.9) | 1 (1.4) | 9 (6.4) |
| 0 | 100 (13.1) | 44 (15.1) | 13 (9.9) | 10 (22.2) | 6 (7.3) | 7 (9.6) | 20 (14.2) |
| 1–3 | 410 (53.7) | 162 (55.5) | 77 (58.8) | 23 (51.1) | 40 (48.8) | 33 (45.2) | 75 (53.2) |
| 4–6 | 232 (30.3) | 78 (26.7) | 41 (31.3) | 12 (26.7) | 32 (39.0) | 32 (43.8) | 37 (26.2) |
| Male (recipient) | 446 (58.4) | 167 (57.2) | 83 (63.4) | 24 (53.3) | 55 (67.1) | 45 (61.6) | 72 (51.1) |
| Male (donor) | 406 (54.0) | 161 (56.1) | 77 (58.8) | 21 (46.7) | 42 (52.5) | 42 (57.5) | 63 (46.3) |
| Donor type | |||||||
| Living related | 451 (59.0) | 190 (65.1) | 75 (57.3) | 27 (60.0) | 43 (52.4) | 34 (46.6) | 82 (58.2) |
| Living unrelated | 141 (18.5) | 42 (14.4) | 35 (26.7) | 4 (8.9) | 18 (22.0) | 18 (24.7) | 24 (17.0) |
| Deceased | 172 (22.5) | 60 (20.5) | 21 (16.0) | 14 (31.1) | 21 (25.6) | 21 (28.7) | 35 (24.8) |
| Referral | |||||||
| Early (≥1 y) | 569 (74.5) | 249 (85.3) | 71 (54.2) | 41 (91.1) | 78 (95.2) | 70 (95.9) | 60 (42.6) |
| Late (<1 y) | 178 (23.3) | 38 (13.0) | 54 (41.2) | 4 (8.9) | 2 (2.4) | 3 (4.1) | 77 (54.6) |
| Unknown | 17 (2.2) | 5 (1.7) | 6 (4.6) | 0 (0) | 2 (2.4) | 0 (0) | 4 (2.8) |
| Pre-emptive | 274 (35.9) | 113 (38.7) | 50 (38.2) | 10 (22.2) | 22 (26.8) | 29 (39.7) | 50 (35.5) |
| Diabetes mellitus | 93 (12.2) | 3 (1.0) | 2 (1.5) | 1 (2.2) | 82 (100.0) | 3 (4.1) | 2 (1.4) |
| Hypertension | 523 (68.5) | 192 (65.8) | 131 (100.0) | 20 (44.4) | 58 (70.7) | 33 (45.2) | 89 (63.1) |
| Immunosuppressants | |||||||
| Calcineurin inhibitors | |||||||
| Cyclosporine A | 369 (48.3) | 137 (46.9) | 71 (54.2) | 20 (44.4) | 42 (51.2) | 27 (37.0) | 72 (51.1) |
| Tacrolimus | 389 (50.9) | 155 (53.1) | 58 (44.3) | 24 (53.4) | 38 (46.4) | 46 (63.0) | 68 (48.2) |
| Others | 6 (0.8) | 0 (0) | 2 (1.5) | 1 (2.2) | 2 (2.4) | 0 (0) | 1 (0.7) |
| Purine synthesis inhibitors | |||||||
| Not use | 82 (10.7) | 35 (12.0) | 17 (13.0) | 5 (11.1) | 2 (2.4) | 8 (11.0) | 15 (10.6) |
| MMF | 574 (75.2) | 215 (73.6) | 90 (68.7) | 34 (75.6) | 77 (93.9) | 56 (76.7) | 102 (72.3) |
| Azathioprine | 107 (14.0) | 41 (14.0) | 24 (18.3) | 6 (13.3) | 3 (3.7) | 9 (12.3) | 24 (17.1) |
| Others | 1 (0.1) | 1 (0.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Basiliximab | 322 (42.1) | 115 (39.4) | 50 (38.2) | 20 (44.4) | 46 (56.1) | 38 (52.1) | 53 (37.6) |
| Age at transplant⁎ | 41.49±11.97 | 38.69±11.06 | 46.18±10.60 | 35.22±12.71 | 52.10±9.18 | 39.84±13.43 | 39.65±10.46 |
| Donor age⁎ | 38.80±12.26 | 38.25±11.71 | 38.58±10.95 | 37.98±12.52 | 40.44±14.77 | 40.79±12.92 | 38.38±12.57 |
HLA, human leukocyte antigen; MMF, mycophenolate mofetil; PN, pyelonephritis.
⁎
Data expressed as mean±standard deviation (in years).